Borden Lacy Archive — Page 1 of 1

The study team includes, from left, Maribeth Nicholson, MD, MPH, Ben Spiller, PhD, Buddy Creech, MD, MPH, Borden Lacy, PhD, Eric Skaar, PhD, MPH, Isaac Thomsen, MD, MSCI, Ivelin Georgiev, PhD, and Danyvid Olivares-Villagomez, PhD.
March 30, 2023

NIH grant launches C. diff vaccine research initiative

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

By Anthony Czelusniak
January 10, 2020

Structural views of a C. diff toxin

D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.

By Leigh MacMillan
Clostridium difficile bacterium, 3D illustration
January 26, 2018

Versatile C. difficile blocker

New research reveals a unique mechanism of C. difficile toxin neutralization by a monoclonal antibody, suggesting new therapeutic approaches.

By Bill Snyder
November 20, 2017

15 faculty members elected as AAAS fellows

Fifteen Vanderbilt faculty members conducting a range of biomedical and clinical research have been elected fellows of the American Association for the Advancement of Science. Six of the 15 have received funding through the university’s Trans-Institutional Programs initiative, which facilitates research and teaching collaborations across disciplines and are a core pillar of the university’s Academic Strategic Plan.

By Bill Snyder
Illustration of human intestinal tract
January 14, 2016

Crystal structure reveals secrets of virulent bacterium

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile (“C. diff”) — the leading cause of hospital-acquired diarrhea in the United States.

By Bill Snyder
arm with IV line
June 4, 2015

Study identifies C. diff toxin receptor, suggests new treatment approaches

Vanderbilt University investigators have identified a cellular receptor for a toxin from Clostridium difficile (“C. diff”) — the leading cause of hospital-acquired diarrhea in the United States.

By Leigh MacMillan